Galapagos (GLPG) Q4 2024 earnings summary

Executive summary

• Announced a strategic plan to separate into two publicly traded entities: Galapagos (cell therapy focus) and SpinCo (pipeline expansion via acquisitions and partnerships), with completion targeted by mid-2025.

• Completed the sale of the Jyseleca business to Alfasigma, achieving €200 million in annualized savings and future royalty eligibility.

• Advanced the GLPG5101 CD19 CAR-T program with FDA IND clearance and strong clinical results in multiple NHL indications.

• Expanded strategic collaborations with Lonza, Thermo Fisher, Adaptimmune, and others.

Financial highlights

• Total 2024 revenues were €275.6 million, up 15% year-over-year, with €35 million from Jyseleca supply and €241 million from collaborations.

• R&D expenses rose 39% year-over-year to €335.5 million, mainly due to oncology CAR-T expansion.

• Net profit for 2024 was €74.1 million, including gains from Jyseleca sale and fair value adjustments.

• Operating loss from continuing operations widened to €188.3 million, reflecting increased R&D investment.

• Ended 2024 with €3.3 billion in cash and investments; cash burn was €374 million.

Outlook and guidance

• Galapagos will be capitalized with €500 million post-separation, providing runway to 2028 with normalized annual cash burn projected at €175–225 million.

• SpinCo will be capitalized with €2.45 billion to pursue pipeline expansion and development.

• Pivotal studies for GLPG5101 planned for 2026, with first approval targeted for 2028.

• Topline results for TYK2 inhibitor GLPG3667 in SLE and DM expected in H1 2026; seeking partners for small molecule assets.

• SpinCo to be listed on Euronext and Nasdaq by mid-2025, with all shareholders receiving SpinCo shares pro rata.